NVSCIK 1114448

NOVARTIS AG

EDGAR filings

Customers

2 federal agencies

Suppliers

0 disclosed

Federal obligations

$7.7M

FY2024 · USAspending.gov

Latest period

Dec 31, 2024

10-K filed 2026-02-12

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 1

Companies that disclose NVS as a major customer, as a share of their own revenue. 0 active, 1 lapsed.

Company	% of their revenue	Est. $ from NVS	Period	Trend	Status	Source
ALNY ALNYLAM PHARMACEUTICALS, INC.	Named	—	FY 2024-12-31	—	Lapsed Last seen 2024-12-31	10-K 2026-02-12
Novartis AG * 23 % 10-K filed 2026-02-12 Period FY 2024-01-01 to 2024-12-31Accession 0001628280-26-007497

Federal contracts 2

Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $10.1M in the latest fiscal year shown per agency.

Agency	Obligated	Fiscal year	Awards	Trend	Largest award
Department of Veterans Affairs Department of Veterans Affairs	$7.7M	FY 2024	14	$19.4M → $7.7M	36C26224F0015
PLUVICTO Award 36C26224F0015 on USAspending.gov ↗ Largest of 14 awards in FY2024: $4.9M obligated
Department of Defense Department of the Army	$2.3M	FY 2023	12		W81K0022P0229
LUTETIUM LU-177VIPIVOTIDE TETRAXETAN Award W81K0022P0229 on USAspending.gov ↗ Largest of 12 awards in FY2023: $1.5M obligated

Alerts are coming

Get an email when NVS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.